Paclitaxel Plus Doxorubicin in Metastatic Breast Ca: The Milan Experience
ثبت نشده
چکیده
Because of the high therapeutic potential of paclitaxel (Taxol) and doxorubicin (Adriamycin) in women with breast cancer, a series of studies evaluating the combination of the two drugs have been undertaken at the National Cancer Institute in Milan, Italy. Investigations aimed at establishing the optimal dosage regimen to maximize the combinations therapeutic effectiveness and to minimize the cardiotoxicity associated with doxorubicin were particularly important.
منابع مشابه
Paclitaxel plus doxorubicin in metastatic breast Ca: the Milan experience.
A pilot study conducted at the National Cancer Institute in Milan, Italy assessed the efficacy of six or eight cycles of paclitaxel (Taxol) 200 mg/m2 q3wks plus doxorubicin (Adriamycin) (60 mg/m2q3wks) in 49 women with metastatic breast cancer who had received no prior chemotherapy. This study suggested that paclitaxel and doxorubicin should be considered for previously untreated patients who h...
متن کاملComparing adverse effects of docetaxel-doxorubicin and paclitaxel-doxorubicin regimens in breast cancer patients
Introduction: Taxanes have emerged as one of the most active agents in the treatment of patients with breast cancer. Nevertheless, questions remain with regard to their toxicity profiles. This study aimed to compare prevalence and severity of adverse effects of two chemotherapy regimens including taxanes (docetaxel or paclitaxel) in breast cancer patients. Materials and Methods: Fifty patients ...
متن کاملMetastatic breast cancer: experience with the combination paclitaxel plus epirubicin.
This study evaluated the safety and feasibility of the combination of paclitaxel (Taxol) and epirubicin, the 4'-epimer of doxorubicin, in women with metastatic breast cancer. A total of 85 patients with histologically proven metastatic breast cancer were treated in two cohorts; epirubicin 60 mg/m2 i.v. infused over 1 hour, followed by paclitaxel 175 mg/m2 i.v. infused over 3 hours (group A), an...
متن کاملSequential dose-dense adjuvant therapy with doxorubicin, paclitaxel, and cyclophosphamide.
The recognition of paclitaxel's (Taxol) activity and non-cross-resistance with doxorubicin (Adriamycin) in the treatment of metastatic breast cancer has motivated study of the agent in the adjuvant setting. However, the ideal means of incorporating this new agent is not yet known. In stage IV disease, exciting results have been seen with combinations of doxorubicin plus paclitaxel, and this app...
متن کاملStrong and Sustained Response to Treatment with Carboplatin plus Nab-Paclitaxel in a Patient with Metastatic, Triple-Negative, BRCA1-Positive Breast Cancer
Our case describes a 51-year-old female, diagnosed in April 2008 with a triple-negative, BRCA1-positive, infiltrating ductal carcinoma of the left breast. Initial platinum-based therapy resulted in a complete regression until November 2009, when a recurrence of the disease was detected. As no evidence of metastasis was found, a dose-dense regimen of doxorubicin plus cyclophosphamide was adminis...
متن کامل